RedChip Interviews Odyssey Health, Inc.’s CEO Michael Redmond
RedChip’s CEO Dave Gentry interviews Odyssey’s CEO Michael Redmond in this exclusive interview, covering the questions on the mind of current and future shareholders.
Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug
Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For Cohort I, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical need.
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial.
